# Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

> **NCT00750737** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Invasive Fungal Infections
- Hematologic Malignancies

## Interventions

- **DRUG:** Posaconazole
- **DRUG:** ABLC

## Key facts

- **NCT ID:** NCT00750737
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750737, "Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00750737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*